肿瘤细胞治疗研究
英文原题：Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma.
自 30 多年前被发现以来，MUC 1 仍是最受关注的肿瘤相关抗原。
黏蛋白1（MUC1）是一种高度糖基化的肿瘤相关抗原（TAA），在肝细胞癌（HCC）中过表达。该蛋白在转录和转录后水平参与多条免疫介导的信号通路，导致HCC免疫逃逸和转移。HCC细胞借助免疫抑制性肿瘤相关抗原维持免疫抑制环境，促进疾病转移扩散。开发强效免疫治疗靶向肿瘤相关抗原，对于克服HCC进展至关重要。自30多年前发现以来，MUC1一直是最受关注的肿瘤相关抗原。目前数种靶向MUC1的有前景免疫疗法正在临床试验中，包括CAR-T和CAR-pNK介导疗法。本文综述MUC1的生物合成、重要性及其作为HCC免疫靶点的临床意义。
Mucin 1 (MUC 1) is a highly glycosylated tumor-associated antigen (TAA) overexpressed in hepatocellular carcinoma (HCC). This protein plays a critical role in various immune-mediated signaling pathways at its transcriptional and post-transcriptional levels, leading to immune evasion and metastasis in HCC. HCC cells maintain an immune-suppressive environment with the help of immunesuppressive tumor-associated antigens, resulting in a metastatic spread of the disease. The development of intense immunotherapeutic strategies to target tumor-associated antigen is critical to overcoming the progression of HCC. MUC 1 remains the most recognized tumor-associated antigen since its discovery over 30 years ago. A few promising immunotherapies targeting MUC 1 are currently under clinical trials, including CAR-T and CAR-pNK-mediated therapies. This review highlights the biosynthesis, significance, and clinical implication of MUC 1 as an immune target in HCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
